Significance of Her-2/neu Protein over Expression in Indian Breast Cancer Patients

Overview

Journal Indian J Surg

Specialty General Surgery

Date 2012 Nov 8

PMID 23132963

Citations 12

Authors

Vikash Kumar

Mallika Tewari

Usha Singh

H S Shukla

Affiliations

Soon will be listed here.

Abstract

Background: Racial disparity in presentation and outcome of breast cancer is established but cause is unexplained. Many studies show various molecular markers for racial differences in the prognosis of breast cancer. There is scarcity of data on prognostic significance of HER-2/neu in Indian breast cancer.

Aims And Objective: To know incidence and prognostic significance of HER-2/neu expression in Indian patients. To correlate HER-2/neu Expression with other prognostic markers and ER/PR Receptor status.

Material And Methods: 112 consecutive patients with breast cancer attending the Department of Surgical Oncology from March 1997 to March 2000 were included in this study. The clinical data along with ER/PR status, follow up data and HER-2/neu expression examined by immuno-histochemical method was recorded.

Statistical Analysis: Data was analyzed by univariate and multivariate analysis for all prognostic factors. Significance was calculated by using Chi square test and survival analysis by using Kaplan Meier survival curve.

Results: The median age of 112 patients was 46.56 (±9.55) years. HER-2/neu over expression was present in 46.37%. Significant correlation was found between HER-2/neu over expression and lymph node status, grade of tumor and ER/PR receptor status. Median follow up period of 23 months. There was significant tumour free survival advantage (p < 0.01) and overall survival advantage (p < 0.001) in patients with HER-2/neu negative expression.

Conclusion: HER-2/neu oncogene over expression is higher (46.37%) among Indian patients in comparison to 25-30% shown in most western literature. HER-2/neu oncogene over expression significantly correlates with grade, lymph node involvement, ER/PR status and also affects survival.

Citing Articles

Clinicopathological Profile of Breast Cancer at a Tertiary Cancer Center in Jharkhand, India: A Descriptive Cohort Study.

Upadhyay A, Prakash A Cureus. 2023; 15(6):e39990.

PMID: 37416049 PMC: 10321568. DOI: 10.7759/cureus.39990.

Correlation of digital mammography and digital breast tomosynthesis features of self-detected breast cancers with human epidermal growth factor receptor type 2/neu status.

Sonthineni C, Mohindra N, Agrawal V, Neyaz Z, Jain N, Mayilvagnan S South Asian J Cancer. 2019; 8(3):140-144.

PMID: 31489283 PMC: 6699222. DOI: 10.4103/sajc.sajc_300_18.

Patterns of Care of Breast Cancer Patients in a Rural Cancer Center in Western India.

Nene B, Selmouni F, Lokhande M, Hingmire S, Muwonge R, Jayant K Indian J Surg Oncol. 2018; 9(3):374-380.

PMID: 30288001 PMC: 6154374. DOI: 10.1007/s13193-018-0748-4.

Improving accuracy of breast cancer biomarker testing in India.

Shet T Indian J Med Res. 2018; 146(4):449-458.

PMID: 29434058 PMC: 5819026. DOI: 10.4103/ijmr.IJMR_896_16.

Androgen Receptor Expression in an Indian Breast Cancer Cohort with Relation to Molecular Subtypes and Response to Neoadjuvant Chemotherapy - a Prospective Clinical Study.

Anand A, Singh K, Kumar S, Husain N, Kushwaha J, Sonkar A Breast Care (Basel). 2017; 12(3):160-164.

PMID: 28785183 PMC: 5527170. DOI: 10.1159/000458433.

References

Perren T . c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer. 1991; 63(3):328-32. PMC: 1971858. DOI: 10.1038/bjc.1991.78. View

Fakhro A, Fateha B, Al-Asheeri N . Breast cancer: patient characteristics and survival analysis at Salmaniya medical complex, Bahrain. East Mediterr Health J. 2000; 5(3):430-9. View

Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F . HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol. 2007; 19(1):56-62. DOI: 10.1097/GCO.0b013e328012980a. View

Malik I . Clinico-pathological features of breast cancer in Pakistan. J Pak Med Assoc. 2002; 52(3):100-4. View

Rose D, Royak-Schaler R . Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect Prev. 2001; 25(1):16-31. View

Tandon A, Clark G, Chamness G, Ullrich A, McGuire W . HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989; 7(8):1120-8. DOI: 10.1200/JCO.1989.7.8.1120. View

Sahin A . Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv Anat Pathol. 2000; 7(3):158-66. DOI: 10.1097/00125480-200007030-00005. View

Ferrero-Pous M, Hacene K, Bouchet C, Le Doussal V, Tubiana-Hulin M, Spyratos F . Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res. 2001; 6(12):4745-54. View

Maalej M, Frikha H, Ben Salem S, Daoud J, Bouaouina N, Ben Abdallah M . [Breast cancer in Tunisia: clinical and epidemiological study]. Bull Cancer. 1999; 86(3):302-6. View

10.

Egervari K, Szollosi Z, Nemes Z . Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract. 2007; 203(3):169-77. DOI: 10.1016/j.prp.2006.12.004. View

11.

Bhatavdekar J, Patel D, Shah N, Vora H, Suthar T, Chikhlikar P . Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis. Ann Surg Oncol. 2000; 7(4):305-11. DOI: 10.1007/s10434-000-0305-5. View

12.

Looi L, Cheah P . C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein. Malays J Pathol. 2000; 20(1):19-23. View

13.

Ciocca D, Gago F, Fanelli M, Calderwood S . Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications. J Steroid Biochem Mol Biol. 2006; 102(1-5):32-40. DOI: 10.1016/j.jsbmb.2006.09.008. View

14.

Ezzat A, Raja M, Zwaan F, Brigden M, Rostom A, Bazarbashi S . The lack of age as a significant prognostic factor in non-metastatic breast cancer. Eur J Surg Oncol. 1998; 24(1):23-7. DOI: 10.1016/s0748-7983(98)80120-0. View

15.

Nunes R, Harris L . The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer. 2002; 3(2):125-35; discussion 136-7. DOI: 10.3816/cbc.2002.n.017. View

16.

Simon M, Severson R . Racial differences in breast cancer survival: the interaction of socioeconomic status and tumor biology. Am J Obstet Gynecol. 1997; 176(6):S233-9. DOI: 10.1016/s0002-9378(97)70381-8. View

17.

Bankfalvi A, Tory K, Kemper M, Breukelmann D, Cubick C, Poremba C . Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. Pathol Res Pract. 2000; 196(7):489-501. DOI: 10.1016/S0344-0338(00)80051-5. View

18.

Slamon D, DeKernion J, Verma I, Cline M . Expression of cellular oncogenes in human malignancies. Science. 1984; 224(4646):256-62. DOI: 10.1126/science.6538699. View

19.

Barbareschi M, Caffo O, Veronese S, Leek R, Fina P, Fox S . Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol. 1996; 27(11):1149-55. DOI: 10.1016/s0046-8177(96)90307-x. View

20.

Ikpatt O, Kuopio T, Collan Y . Proliferation in African breast cancer: biology and prognostication in nigerian breast cancer material. Mod Pathol. 2002; 15(8):783-9. DOI: 10.1097/01.MP.0000021764.03552.BD. View